Skip to main content

Featured

Chinese Stocks Plummet Amid Stimulus Concerns

  Chinese stocks experienced a significant downturn today, with the Shanghai Composite Index plummeting by 6.6%. This sharp decline comes as investors express growing anxiety over the lack of substantial economic stimulus from Beijing. The market’s reaction follows recent rallies driven by hopes for major economic interventions. However, the latest announcements from Chinese officials have failed to meet these expectations, leading to widespread sell-offs. The CSI300 Index, which tracks the top 300 stocks in the Shanghai and Shenzhen markets, also saw a substantial drop of 5.6%. Hong Kong’s Hang Seng Index was not spared, falling by 1.5% as investors moved to lock in profits after recent gains. The lack of new, impactful fiscal policies has left many market participants disappointed, contributing to the overall negative sentiment. Analysts suggest that the market’s response is a clear signal of diminishing confidence in half-hearted promises and a demand for more decisive economic meas
Post a Comment
Read more
Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment